Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Chamoto

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Leukemia|February 25, 2020
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphomaMasaharu Kawashima, Joaquim Carreras, Hiroshi Higuchi, et al.
Nature Immunology|October 24, 2017
Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behaviorMichio Miyajima, Baihao Zhang, Yuki Sugiura, et al.
Science (New York, N.Y.)|October 27, 2022
Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in miceMuna Al-Habsi, Kenji Chamoto, Ken Matsumoto, et al.
JTO Clinical and Research Reports|November 29, 2023
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant ChemotherapyJunko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, et al.
Science Translational Medicine|December 14, 2022
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancerKentaro Tanaka, Kenji Chamoto, Sho Saeki, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2023
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trialHisato Kawakami, Yu Sunakawa, Eisuke Inoue, et al.
The Journal of Clinical Investigation|April 1, 2024
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockadeHidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
Nature|November 4, 2021
B cell-derived GABA elicits IL-10<sup>+</sup> macrophages to limit anti-tumour immunityBaihao Zhang, Alexis Vogelzang, Michio Miyajima, et al.
Nature Medicine|June 25, 2026
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profilingDéborah Suissa, Marine Fidelle, Ella Reich, et al.
Nature Medicine|June 29, 2021
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a childMasato Ogishi, Rui Yang, Caner Aytekin, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Leukemia|February 25, 2020
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphomaMasaharu Kawashima, Joaquim Carreras, Hiroshi Higuchi, et al.
Nature Immunology|October 24, 2017
Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behaviorMichio Miyajima, Baihao Zhang, Yuki Sugiura, et al.
Science (New York, N.Y.)|October 27, 2022
Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in miceMuna Al-Habsi, Kenji Chamoto, Ken Matsumoto, et al.
JTO Clinical and Research Reports|November 29, 2023
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant ChemotherapyJunko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, et al.
Science Translational Medicine|December 14, 2022
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancerKentaro Tanaka, Kenji Chamoto, Sho Saeki, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2023
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trialHisato Kawakami, Yu Sunakawa, Eisuke Inoue, et al.
The Journal of Clinical Investigation|April 1, 2024
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockadeHidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
Nature|November 4, 2021
B cell-derived GABA elicits IL-10<sup>+</sup> macrophages to limit anti-tumour immunityBaihao Zhang, Alexis Vogelzang, Michio Miyajima, et al.
Nature Medicine|June 25, 2026
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profilingDéborah Suissa, Marine Fidelle, Ella Reich, et al.
Nature Medicine|June 29, 2021
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a childMasato Ogishi, Rui Yang, Caner Aytekin, et al.
Pageof 11